Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

info@aumed.cz+420 603 587 701 English

TRANSFER FACTOR

Aumed, a.s.Transfer factor

Research and development of transfer factors in the company AUMED, a.s.

AUMED, a.s. focuses on one of its research and development activities, supported by grants, to the area of transfer factors intended for human therapy.

WHAT ARE THE TRANSFER FACTORS?

Transfer factors were discovered and described by Dr. Henry Sherwood Lawrence in the late 1940s. It is still an inaccurately defined mixture of many biologically active molecules carrying immunity information. They represent a unique type of messenger used for cell-to-cell communication in the immune system.

The essence of the efficiency of transfer factors lies in the transfer of distinct cell-mediated immunity from an immuno-sufficient donor to a deficient recipient. Transfer factors have been used successfully over the past quarter of a century for treating viral, parasitic, and fungal infections, as well as immunodeficiencies, neoplasias, allergies and autoimmune diseases. Moreover, case reports in cancer treatment have been published.

WHY RESEARCH IN THIS AREA?

The development of legislation related to pharmaceutical issues generally puts increasing emphasis on the safety and efficacy of medicines. The research activities of transfer factors in AUMED, a.s. therefore focus on modernization of their preparation technology, more precise identification of the mechanism of their effects, development of more sophisticated procedures of their testing and innovation of their pharmaceutical form.

AIM OF OUR RESEARCH

All of these research activities should result in a transfer factor as a new medicinal product that meets all the criteria for advanced drugs. The innovatively enhanced immunotherapy medical product will not only have good commercial use, but above all a wide therapeutic application and good potential in a diverse range of increasing immunological diseases.

Research was also supported by the OPPIK project (PROJECT NUMBER: CZ.01.1.02/0.0/0.0/16_083/0010301). This project was successfully completed in 2020. The main output of the project are produced samples – lyophilized tablets containing transfer factor as an active drug substance. Learn more about the results of the project.

We assume that the results of the presented project will probably be followed by a series of other tests (clinical) needed for the marketing of the drug.

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701, Email: info@aumed.cz
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s